Log In
BCIQ
Print this Print this
 

Relenza intravenous, zanamivir

  Manage Alerts
Collapse Summary General Information
Company Aviragen Therapeutics Inc.
DescriptionIntravenous formulation of Relenza (zanamivir)
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationInfluenza virus
Indication DetailsTreat and prevent influenza virus infection
Regulatory Designation
PartnerGlaxoSmithKline plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today